GlucoTrack, Inc.
GlucoTrack, Inc. GCTK Peers
See (GCTK) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GCTK | $6.27 | -20.03% | 3M | N/A | -$3,442.80 | N/A |
| ISRG | $535.53 | +2.66% | 191.5B | 78.24 | $6.83 | N/A |
| BDXA | $59.24 | -2.24% | 49.5B | 21.44 | $2.76 | +2.40% |
| BDX | $170.51 | -0.23% | 48.7B | 32.94 | $5.16 | +2.40% |
| ALC | $87.44 | -0.15% | 43.1B | 38.72 | $2.25 | +0.38% |
| RMD | $254.20 | -1.44% | 37.6B | 28.76 | $8.91 | +0.83% |
| WST | $217.56 | -1.57% | 15.7B | 34.44 | $6.36 | +0.38% |
| BAX | $30.52 | -0.29% | 15.7B | -58.67 | -$0.52 | +2.63% |
| HOLX | $65.10 | +1.29% | 14.5B | 27.36 | $2.38 | N/A |
| COO | $70.24 | +1.00% | 13.9B | 33.67 | $2.07 | N/A |
Stock Comparison
GCTK vs ISRG Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, ISRG has a market cap of 191.5B. Regarding current trading prices, GCTK is priced at $6.27, while ISRG trades at $535.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas ISRG's P/E ratio is 78.24. In terms of profitability, GCTK's ROE is +3.93%, compared to ISRG's ROE of +0.16%. Regarding short-term risk, GCTK is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs BDXA Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, BDXA has a market cap of 49.5B. Regarding current trading prices, GCTK is priced at $6.27, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas BDXA's P/E ratio is 21.44. In terms of profitability, GCTK's ROE is +3.93%, compared to BDXA's ROE of +0.06%. Regarding short-term risk, GCTK is more volatile compared to BDXA. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs BDX Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, BDX has a market cap of 48.7B. Regarding current trading prices, GCTK is priced at $6.27, while BDX trades at $170.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas BDX's P/E ratio is 32.94. In terms of profitability, GCTK's ROE is +3.93%, compared to BDX's ROE of +0.06%. Regarding short-term risk, GCTK is more volatile compared to BDX. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs ALC Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, ALC has a market cap of 43.1B. Regarding current trading prices, GCTK is priced at $6.27, while ALC trades at $87.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas ALC's P/E ratio is 38.72. In terms of profitability, GCTK's ROE is +3.93%, compared to ALC's ROE of +0.07%. Regarding short-term risk, GCTK is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs RMD Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, RMD has a market cap of 37.6B. Regarding current trading prices, GCTK is priced at $6.27, while RMD trades at $254.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas RMD's P/E ratio is 28.76. In terms of profitability, GCTK's ROE is +3.93%, compared to RMD's ROE of +0.25%. Regarding short-term risk, GCTK is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs WST Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, WST has a market cap of 15.7B. Regarding current trading prices, GCTK is priced at $6.27, while WST trades at $217.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas WST's P/E ratio is 34.44. In terms of profitability, GCTK's ROE is +3.93%, compared to WST's ROE of +0.17%. Regarding short-term risk, GCTK is more volatile compared to WST. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs BAX Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, BAX has a market cap of 15.7B. Regarding current trading prices, GCTK is priced at $6.27, while BAX trades at $30.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas BAX's P/E ratio is -58.67. In terms of profitability, GCTK's ROE is +3.93%, compared to BAX's ROE of -0.08%. Regarding short-term risk, GCTK is more volatile compared to BAX. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs HOLX Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, HOLX has a market cap of 14.5B. Regarding current trading prices, GCTK is priced at $6.27, while HOLX trades at $65.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas HOLX's P/E ratio is 27.36. In terms of profitability, GCTK's ROE is +3.93%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, GCTK is more volatile compared to HOLX. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs COO Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, COO has a market cap of 13.9B. Regarding current trading prices, GCTK is priced at $6.27, while COO trades at $70.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas COO's P/E ratio is 33.67. In terms of profitability, GCTK's ROE is +3.93%, compared to COO's ROE of +0.05%. Regarding short-term risk, GCTK is more volatile compared to COO. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs BDXB Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, GCTK is priced at $6.27, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas BDXB's P/E ratio is 7.60. In terms of profitability, GCTK's ROE is +3.93%, compared to BDXB's ROE of +0.06%. Regarding short-term risk, GCTK is more volatile compared to BDXB. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs ATR Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, ATR has a market cap of 10.2B. Regarding current trading prices, GCTK is priced at $6.27, while ATR trades at $154.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas ATR's P/E ratio is 28.24. In terms of profitability, GCTK's ROE is +3.93%, compared to ATR's ROE of +0.15%. Regarding short-term risk, GCTK is more volatile compared to ATR. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs MASI Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, MASI has a market cap of 9B. Regarding current trading prices, GCTK is priced at $6.27, while MASI trades at $165.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas MASI's P/E ratio is -30.48. In terms of profitability, GCTK's ROE is +3.93%, compared to MASI's ROE of -0.41%. Regarding short-term risk, GCTK is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs RGEN Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, RGEN has a market cap of 7B. Regarding current trading prices, GCTK is priced at $6.27, while RGEN trades at $123.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas RGEN's P/E ratio is -295.74. In terms of profitability, GCTK's ROE is +3.93%, compared to RGEN's ROE of -0.01%. Regarding short-term risk, GCTK is more volatile compared to RGEN. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs STVN Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, STVN has a market cap of 6.9B. Regarding current trading prices, GCTK is priced at $6.27, while STVN trades at $24.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas STVN's P/E ratio is 47.44. In terms of profitability, GCTK's ROE is +3.93%, compared to STVN's ROE of +0.09%. Regarding short-term risk, GCTK is more volatile compared to STVN. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs MMSI Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, MMSI has a market cap of 5.5B. Regarding current trading prices, GCTK is priced at $6.27, while MMSI trades at $92.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas MMSI's P/E ratio is 45.49. In terms of profitability, GCTK's ROE is +3.93%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, GCTK is more volatile compared to MMSI. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs TFX Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, TFX has a market cap of 5.3B. Regarding current trading prices, GCTK is priced at $6.27, while TFX trades at $119.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas TFX's P/E ratio is 37.00. In terms of profitability, GCTK's ROE is +3.93%, compared to TFX's ROE of +0.03%. Regarding short-term risk, GCTK is more volatile compared to TFX. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs BLCO Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, BLCO has a market cap of 4.3B. Regarding current trading prices, GCTK is priced at $6.27, while BLCO trades at $12.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas BLCO's P/E ratio is -11.83. In terms of profitability, GCTK's ROE is +3.93%, compared to BLCO's ROE of -0.08%. Regarding short-term risk, GCTK is more volatile compared to BLCO. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs HAE Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, HAE has a market cap of 3.6B. Regarding current trading prices, GCTK is priced at $6.27, while HAE trades at $74.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas HAE's P/E ratio is 22.61. In terms of profitability, GCTK's ROE is +3.93%, compared to HAE's ROE of +0.18%. Regarding short-term risk, GCTK is more volatile compared to HAE. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs ICUI Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, ICUI has a market cap of 3.2B. Regarding current trading prices, GCTK is priced at $6.27, while ICUI trades at $128.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas ICUI's P/E ratio is -34.10. In terms of profitability, GCTK's ROE is +3.93%, compared to ICUI's ROE of -0.05%. Regarding short-term risk, GCTK is more volatile compared to ICUI. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs XRAY Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, XRAY has a market cap of 3.2B. Regarding current trading prices, GCTK is priced at $6.27, while XRAY trades at $15.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas XRAY's P/E ratio is -3.58. In terms of profitability, GCTK's ROE is +3.93%, compared to XRAY's ROE of -0.38%. Regarding short-term risk, GCTK is more volatile compared to XRAY. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs WRBY Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, WRBY has a market cap of 2.6B. Regarding current trading prices, GCTK is priced at $6.27, while WRBY trades at $21.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas WRBY's P/E ratio is -178.92. In terms of profitability, GCTK's ROE is +3.93%, compared to WRBY's ROE of -0.04%. Regarding short-term risk, GCTK is more volatile compared to WRBY. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs QDEL Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, QDEL has a market cap of 1.9B. Regarding current trading prices, GCTK is priced at $6.27, while QDEL trades at $28.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas QDEL's P/E ratio is -5.49. In terms of profitability, GCTK's ROE is +3.93%, compared to QDEL's ROE of -0.11%. Regarding short-term risk, GCTK is more volatile compared to QDEL. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs NVCR Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, NVCR has a market cap of 1.9B. Regarding current trading prices, GCTK is priced at $6.27, while NVCR trades at $17.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas NVCR's P/E ratio is -11.32. In terms of profitability, GCTK's ROE is +3.93%, compared to NVCR's ROE of -0.45%. Regarding short-term risk, GCTK is more volatile compared to NVCR. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs LMAT Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, LMAT has a market cap of 1.9B. Regarding current trading prices, GCTK is priced at $6.27, while LMAT trades at $82.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas LMAT's P/E ratio is 41.83. In terms of profitability, GCTK's ROE is +3.93%, compared to LMAT's ROE of +0.14%. Regarding short-term risk, GCTK is more volatile compared to LMAT. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs ATRC Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, ATRC has a market cap of 1.6B. Regarding current trading prices, GCTK is priced at $6.27, while ATRC trades at $32.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas ATRC's P/E ratio is -40.59. In terms of profitability, GCTK's ROE is +3.93%, compared to ATRC's ROE of -0.08%. Regarding short-term risk, GCTK is more volatile compared to ATRC. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs NNNN Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, NNNN has a market cap of 1.5B. Regarding current trading prices, GCTK is priced at $6.27, while NNNN trades at $32.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas NNNN's P/E ratio is 672.80. In terms of profitability, GCTK's ROE is +3.93%, compared to NNNN's ROE of +0.14%. Regarding short-term risk, GCTK is more volatile compared to NNNN. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs AZTA Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, AZTA has a market cap of 1.4B. Regarding current trading prices, GCTK is priced at $6.27, while AZTA trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas AZTA's P/E ratio is -9.41. In terms of profitability, GCTK's ROE is +3.93%, compared to AZTA's ROE of -0.04%. Regarding short-term risk, GCTK is more volatile compared to AZTA. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs BLFS Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, BLFS has a market cap of 1B. Regarding current trading prices, GCTK is priced at $6.27, while BLFS trades at $21.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas BLFS's P/E ratio is -113.05. In terms of profitability, GCTK's ROE is +3.93%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, GCTK is more volatile compared to BLFS. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs PLSE Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, PLSE has a market cap of 1B. Regarding current trading prices, GCTK is priced at $6.27, while PLSE trades at $14.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas PLSE's P/E ratio is -15.04. In terms of profitability, GCTK's ROE is +3.93%, compared to PLSE's ROE of -0.71%. Regarding short-term risk, GCTK is more volatile compared to PLSE. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs KMTS Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, KMTS has a market cap of 919.1M. Regarding current trading prices, GCTK is priced at $6.27, while KMTS trades at $17.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas KMTS's P/E ratio is -9.32. In terms of profitability, GCTK's ROE is +3.93%, compared to KMTS's ROE of +0.27%. Regarding short-term risk, GCTK is more volatile compared to KMTS. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs STAA Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, STAA has a market cap of 833.5M. Regarding current trading prices, GCTK is priced at $6.27, while STAA trades at $16.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas STAA's P/E ratio is -11.69. In terms of profitability, GCTK's ROE is +3.93%, compared to STAA's ROE of -0.18%. Regarding short-term risk, GCTK is more volatile compared to STAA. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs ATRI Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, GCTK is priced at $6.27, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas ATRI's P/E ratio is 64.50. In terms of profitability, GCTK's ROE is +3.93%, compared to ATRI's ROE of +0.04%. Regarding short-term risk, GCTK is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs ANGO Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, ANGO has a market cap of 400.8M. Regarding current trading prices, GCTK is priced at $6.27, while ANGO trades at $9.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas ANGO's P/E ratio is -9.77. In terms of profitability, GCTK's ROE is +3.93%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, GCTK is more volatile compared to ANGO. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs NYXH Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, NYXH has a market cap of 287.5M. Regarding current trading prices, GCTK is priced at $6.27, while NYXH trades at $7.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas NYXH's P/E ratio is -3.34. In terms of profitability, GCTK's ROE is +3.93%, compared to NYXH's ROE of -0.56%. Regarding short-term risk, GCTK is more volatile compared to NYXH. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs SMTI Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, SMTI has a market cap of 252.1M. Regarding current trading prices, GCTK is priced at $6.27, while SMTI trades at $28.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas SMTI's P/E ratio is -21.16. In terms of profitability, GCTK's ROE is +3.93%, compared to SMTI's ROE of -0.29%. Regarding short-term risk, GCTK is more volatile compared to SMTI. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs OSUR Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, OSUR has a market cap of 225.9M. Regarding current trading prices, GCTK is priced at $6.27, while OSUR trades at $3.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas OSUR's P/E ratio is -7.19. In terms of profitability, GCTK's ROE is +3.93%, compared to OSUR's ROE of -0.08%. Regarding short-term risk, GCTK is more volatile compared to OSUR. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs STXS Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, STXS has a market cap of 188.3M. Regarding current trading prices, GCTK is priced at $6.27, while STXS trades at $2.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas STXS's P/E ratio is -7.06. In terms of profitability, GCTK's ROE is +3.93%, compared to STXS's ROE of -2.17%. Regarding short-term risk, GCTK is more volatile compared to STXS. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs UTMD Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, UTMD has a market cap of 183.3M. Regarding current trading prices, GCTK is priced at $6.27, while UTMD trades at $56.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas UTMD's P/E ratio is 14.89. In terms of profitability, GCTK's ROE is +3.93%, compared to UTMD's ROE of +0.11%. Regarding short-term risk, GCTK is more volatile compared to UTMD. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs KRMD Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, KRMD has a market cap of 165.2M. Regarding current trading prices, GCTK is priced at $6.27, while KRMD trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas KRMD's P/E ratio is -29.83. In terms of profitability, GCTK's ROE is +3.93%, compared to KRMD's ROE of -0.30%. Regarding short-term risk, GCTK is more volatile compared to KRMD. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs PDEX Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, PDEX has a market cap of 140.6M. Regarding current trading prices, GCTK is priced at $6.27, while PDEX trades at $42.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas PDEX's P/E ratio is 15.62. In terms of profitability, GCTK's ROE is +3.93%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, GCTK is more volatile compared to PDEX. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs ZTEK Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, ZTEK has a market cap of 137.2M. Regarding current trading prices, GCTK is priced at $6.27, while ZTEK trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas ZTEK's P/E ratio is -16.44. In terms of profitability, GCTK's ROE is +3.93%, compared to ZTEK's ROE of -0.58%. Regarding short-term risk, GCTK is more volatile compared to ZTEK. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs INFU Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, INFU has a market cap of 134.9M. Regarding current trading prices, GCTK is priced at $6.27, while INFU trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas INFU's P/E ratio is 42.87. In terms of profitability, GCTK's ROE is +3.93%, compared to INFU's ROE of +0.08%. Regarding short-term risk, GCTK is more volatile compared to INFU. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs ZJYL Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, ZJYL has a market cap of 102.3M. Regarding current trading prices, GCTK is priced at $6.27, while ZJYL trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas ZJYL's P/E ratio is 32.68. In terms of profitability, GCTK's ROE is +3.93%, compared to ZJYL's ROE of +0.13%. Regarding short-term risk, GCTK is more volatile compared to ZJYL. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs MBOT Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, MBOT has a market cap of 90.9M. Regarding current trading prices, GCTK is priced at $6.27, while MBOT trades at $2.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas MBOT's P/E ratio is -3.91. In terms of profitability, GCTK's ROE is +3.93%, compared to MBOT's ROE of -0.85%. Regarding short-term risk, GCTK is more volatile compared to MBOT. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs AKYA Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, AKYA has a market cap of 66.2M. Regarding current trading prices, GCTK is priced at $6.27, while AKYA trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas AKYA's P/E ratio is -1.38. In terms of profitability, GCTK's ROE is +3.93%, compared to AKYA's ROE of -5.06%. Regarding short-term risk, GCTK is more volatile compared to AKYA. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs MLSS Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, MLSS has a market cap of 56.8M. Regarding current trading prices, GCTK is priced at $6.27, while MLSS trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas MLSS's P/E ratio is -12.07. In terms of profitability, GCTK's ROE is +3.93%, compared to MLSS's ROE of -0.83%. Regarding short-term risk, GCTK is more volatile compared to MLSS. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs OMIC Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, GCTK is priced at $6.27, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas OMIC's P/E ratio is -0.58. In terms of profitability, GCTK's ROE is +3.93%, compared to OMIC's ROE of -0.58%. Regarding short-term risk, GCTK is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs IGAP Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, GCTK is priced at $6.27, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas IGAP's P/E ratio is -10.52. In terms of profitability, GCTK's ROE is +3.93%, compared to IGAP's ROE of +3.93%. Regarding short-term risk, GCTK is more volatile compared to IGAP. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs DXR Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, DXR has a market cap of 48.2M. Regarding current trading prices, GCTK is priced at $6.27, while DXR trades at $9.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas DXR's P/E ratio is -108.00. In terms of profitability, GCTK's ROE is +3.93%, compared to DXR's ROE of +0.02%. Regarding short-term risk, GCTK is more volatile compared to DXR. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs NEPH Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, NEPH has a market cap of 44.9M. Regarding current trading prices, GCTK is priced at $6.27, while NEPH trades at $4.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas NEPH's P/E ratio is 53.00. In terms of profitability, GCTK's ROE is +3.93%, compared to NEPH's ROE of +0.09%. Regarding short-term risk, GCTK is more volatile compared to NEPH. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs POCI Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, POCI has a market cap of 35M. Regarding current trading prices, GCTK is priced at $6.27, while POCI trades at $4.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas POCI's P/E ratio is -5.02. In terms of profitability, GCTK's ROE is +3.93%, compared to POCI's ROE of -0.54%. Regarding short-term risk, GCTK is more volatile compared to POCI. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs SDC Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, GCTK is priced at $6.27, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas SDC's P/E ratio is -0.03. In terms of profitability, GCTK's ROE is +3.93%, compared to SDC's ROE of -1.96%. Regarding short-term risk, GCTK is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for GCTK.
GCTK vs FEMY Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, FEMY has a market cap of 28.7M. Regarding current trading prices, GCTK is priced at $6.27, while FEMY trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas FEMY's P/E ratio is -1.08. In terms of profitability, GCTK's ROE is +3.93%, compared to FEMY's ROE of -3.92%. Regarding short-term risk, GCTK is more volatile compared to FEMY. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs IVC Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, GCTK is priced at $6.27, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas IVC's P/E ratio is -0.79. In terms of profitability, GCTK's ROE is +3.93%, compared to IVC's ROE of -0.46%. Regarding short-term risk, GCTK is more volatile compared to IVC. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs HBIO Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, HBIO has a market cap of 22.6M. Regarding current trading prices, GCTK is priced at $6.27, while HBIO trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas HBIO's P/E ratio is -0.39. In terms of profitability, GCTK's ROE is +3.93%, compared to HBIO's ROE of -1.10%. Regarding short-term risk, GCTK is more volatile compared to HBIO. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs RVP Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, RVP has a market cap of 19.8M. Regarding current trading prices, GCTK is priced at $6.27, while RVP trades at $0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas RVP's P/E ratio is -0.87. In terms of profitability, GCTK's ROE is +3.93%, compared to RVP's ROE of -0.27%. Regarding short-term risk, GCTK is more volatile compared to RVP. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs WOK Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, WOK has a market cap of 18.4M. Regarding current trading prices, GCTK is priced at $6.27, while WOK trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas WOK's P/E ratio is -2.74. In terms of profitability, GCTK's ROE is +3.93%, compared to WOK's ROE of -0.30%. Regarding short-term risk, GCTK is more volatile compared to WOK. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs NXGL Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, NXGL has a market cap of 18.4M. Regarding current trading prices, GCTK is priced at $6.27, while NXGL trades at $2.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas NXGL's P/E ratio is -5.33. In terms of profitability, GCTK's ROE is +3.93%, compared to NXGL's ROE of -0.63%. Regarding short-term risk, GCTK is more volatile compared to NXGL. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs NXGLW Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, NXGLW has a market cap of 17.1M. Regarding current trading prices, GCTK is priced at $6.27, while NXGLW trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas NXGLW's P/E ratio is -0.19. In terms of profitability, GCTK's ROE is +3.93%, compared to NXGLW's ROE of -0.63%. Regarding short-term risk, GCTK is less volatile compared to NXGLW. This indicates potentially lower risk in terms of short-term price fluctuations for GCTK.
GCTK vs MHUA Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, MHUA has a market cap of 13.9M. Regarding current trading prices, GCTK is priced at $6.27, while MHUA trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas MHUA's P/E ratio is 1.10. In terms of profitability, GCTK's ROE is +3.93%, compared to MHUA's ROE of +0.09%. Regarding short-term risk, GCTK is more volatile compared to MHUA. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs LUCYW Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, LUCYW has a market cap of 13.8M. Regarding current trading prices, GCTK is priced at $6.27, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas LUCYW's P/E ratio is N/A. In terms of profitability, GCTK's ROE is +3.93%, compared to LUCYW's ROE of -0.95%. Regarding short-term risk, GCTK is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for GCTK.
GCTK vs EKSO Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, EKSO has a market cap of 8.6M. Regarding current trading prices, GCTK is priced at $6.27, while EKSO trades at $3.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas EKSO's P/E ratio is -0.50. In terms of profitability, GCTK's ROE is +3.93%, compared to EKSO's ROE of -0.82%. Regarding short-term risk, GCTK is more volatile compared to EKSO. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs POAI Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, POAI has a market cap of 7.7M. Regarding current trading prices, GCTK is priced at $6.27, while POAI trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas POAI's P/E ratio is -0.60. In terms of profitability, GCTK's ROE is +3.93%, compared to POAI's ROE of -5.91%. Regarding short-term risk, GCTK is more volatile compared to POAI. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs LUCY Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, LUCY has a market cap of 6.3M. Regarding current trading prices, GCTK is priced at $6.27, while LUCY trades at $2.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas LUCY's P/E ratio is 0.04. In terms of profitability, GCTK's ROE is +3.93%, compared to LUCY's ROE of -0.95%. Regarding short-term risk, GCTK is more volatile compared to LUCY. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs STSS Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, STSS has a market cap of 5.6M. Regarding current trading prices, GCTK is priced at $6.27, while STSS trades at $5.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas STSS's P/E ratio is N/A. In terms of profitability, GCTK's ROE is +3.93%, compared to STSS's ROE of -0.99%. Regarding short-term risk, GCTK is more volatile compared to STSS. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs NSTG Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, GCTK is priced at $6.27, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas NSTG's P/E ratio is -0.03. In terms of profitability, GCTK's ROE is +3.93%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, GCTK is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for GCTK.
GCTK vs GMVD Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, GCTK is priced at $6.27, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas GMVD's P/E ratio is -0.01. In terms of profitability, GCTK's ROE is +3.93%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, GCTK is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for GCTK.
GCTK vs GMVDW Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, GCTK is priced at $6.27, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas GMVDW's P/E ratio is N/A. In terms of profitability, GCTK's ROE is +3.93%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, GCTK is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for GCTK.
GCTK vs AVGR Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, GCTK is priced at $6.27, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas AVGR's P/E ratio is -0.05. In terms of profitability, GCTK's ROE is +3.93%, compared to AVGR's ROE of -54.25%. Regarding short-term risk, GCTK is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for GCTK.
GCTK vs APR Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, APR has a market cap of 0. Regarding current trading prices, GCTK is priced at $6.27, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas APR's P/E ratio is 22.59. In terms of profitability, GCTK's ROE is +3.93%, compared to APR's ROE of +9.81%. Regarding short-term risk, GCTK is more volatile compared to APR. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs IIN Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, IIN has a market cap of 0. Regarding current trading prices, GCTK is priced at $6.27, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas IIN's P/E ratio is 226.45. In terms of profitability, GCTK's ROE is +3.93%, compared to IIN's ROE of -0.00%. Regarding short-term risk, GCTK is more volatile compared to IIN. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs LMNX Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, LMNX has a market cap of 0. Regarding current trading prices, GCTK is priced at $6.27, while LMNX trades at $36.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas LMNX's P/E ratio is N/A. In terms of profitability, GCTK's ROE is +3.93%, compared to LMNX's ROE of +0.03%. Regarding short-term risk, GCTK is more volatile compared to LMNX. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs ATRS Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, GCTK is priced at $6.27, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas ATRS's P/E ratio is 14.95. In terms of profitability, GCTK's ROE is +3.93%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, GCTK is more volatile compared to ATRS. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.
GCTK vs HRC Comparison
GCTK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GCTK stands at 3M. In comparison, HRC has a market cap of 0. Regarding current trading prices, GCTK is priced at $6.27, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GCTK currently has a P/E ratio of N/A, whereas HRC's P/E ratio is 41.92. In terms of profitability, GCTK's ROE is +3.93%, compared to HRC's ROE of +0.14%. Regarding short-term risk, GCTK is more volatile compared to HRC. This indicates potentially higher risk in terms of short-term price fluctuations for GCTK.